Abstract: The present invention provides methods of using mannose receptor blocker to treat airway disease such as asthma. The present invention also provides methods for reducing smooth muscle mass in an individual having an airway disease.

Abstract: The invention relates to methods for inducing marrow stromal cells to differentiate into neural cells by way of increasing intracellular levels of cyclic AMP. The invention also encompasses methods of producing a neural cell by causing a marrow stromal cell to differentiate into a neural cell by increasing intracellular levels of cyclic AMP. Methods for treating a human patient in need of neural cells are also disclosed, as well as methods for treating a human patient having a disease, condition, or disorder of the central nervous system.

Abstract: The present invention provides recombinant triple helical proteins or collagen-like proteins comprising a prokaryotic protein or one or more domains of a prokaryotic protein comprising a collagen-like peptide sequence of repeated Gly-Xaa-Yaa triplets and, optionally, one or more domains from a mammalian collagen. Also provided are expression vectors and host cells containing the expression vectors to produce these recombinant proteins and methods of production for the same. Additionally, antibodies are provided that are directed against a recombinant collagen-like protein that, preferably, binds an integrin. Furthermore, a method of screening for potential therapeutic compounds that inhibit the integrin-binding or -interacting activities of recombinant collagen-like proteins.

Abstract: The invention provides a method of decreasing pain in a subject, the method comprising administering to the subject an amount of a compound effective to decrease activation of protease activated receptor-2.

Abstract: The present invention provides a DNA encoding a TADG-14 protein selected from the group consisting of: (a) isolated DNA which encodes a TADG-14 protein; (b) isolated DNA which hybridizes to isolated DNA of (a) above and which encodes a TADG-14 protein; and (c) isolated DNA differing from the isolated DNAs of (a) and (b) above in codon sequence due to the degeneracy of the genetic code, and which encodes a TADG-14 protein. Also provided is a vector capable of expressing the DNA of the present invention adapted for expression in a recombinant cell and regulatory elements necessary for expression of the DNA in the cell.

Abstract: Software for designing optimized sets of oligonucleotide probes for use in genosensors (oligonucleotide microarrays) is disclosed. The selection of probe sequences is based on multiple criteria including thermal stability of the probe-target pairs, similarity degree of the probes with respect to other DNA sequences, and evaluation of the secondary structure of target molecules. The programs were written in the programming language Borland Delphi by means of Object-Oriented Programming (OOP) techniques. The Genosensor Probe Design computer program disclosed herein facilitates the design of optimized arrays of probes which accurately represents the characteristics of the nucleic acid molecule under study, such as its identity or its differences in sequence or abundance with respect to other molecules.

Abstract: Improved methods for the production, selection and inhibition of catalytic antibodies are disclosed.

Abstract: Disclosed are isolated IKK??; isolated nucleic acid molecules encoding IKK??; expression vectors and cells which contain such nucleic acid molecules; oligonucleotides which are complementary to at least a portion of nucleic acid molecules encoding IKK?? but which are not complementary to any portion of nucleic acid molecules encoding wild type IKK?; antibodies which are specific for IKK??; DNA and RNA oligomers, optionally in labeled or enzymatically active form, which are capable of selectively hybridizing to nucleic acid molecules encoding IKK??; and DNA and RNA oligomers, optionally in labeled or enzymatically active form, which are capable of selectively hybridizing to nucleic acid molecules encoding IKK?? but which do not hybridize with nucleic acid molecules encoding wild type IKK?. Methods for using these materials to inhibit formation of IKK??-containing IKK, to inhibit NF-?B activation, and to treat or prevent inflammation are also disclosed.

Abstract: The present invention identified a high affinity binding sequence in collagen type III for the collagen-binding integrin I domains. Provided herein are the methods used to characterize the sequence, the peptides comprising this novel sequence and the use of the peptides in enabling cell adhesion. Also provided herein are methods to identify specific integrin inhibitors, sequences of these inhibitors and their use in inhibiting pathophysiological conditions that may arise due to integrin-collagen interaction.

Abstract: A method of enhancing detection for a specific object in a body. A nanoparticulate is administered to the body for location in an area to be explored for detection of the object, if present. The nanoparticulate is at least partially metallic, has a formed non-spherical shape having a minimal characteristic dimension in the range from about 1 to about 3000 nanometers, and has a formed composition capable of producing thermal pressure either in the nanoparticulate or in the object greater than the object could produce in the absence of the nanoparticulate. Electromagnetic radiation is directed into the body. The electromagnetic radiation has a specific wavelength or spectrum of wavelengths in the range from 300 nm to 300 mm selected so that the wavelength or wavelength spectrum is longer by a factor of at least 3 than the minimum characteristic dimension of the nanoparticulate.

Abstract: The present invention provides genomic and cDNA encoding human cytoplasmic polyadenylation element binding protein, expression vectors comprising human cytoplasmic polyadenylation element binding protein cDNA and host cells that contain the expression vectors. Also provided are recombinant human cytoplasmic polyadenylation element binding protein and polypeptides derived thereof. In addition, the present invention reports that the human Mos 3? untranslated region (3? UTR) contains a functional cytoplasmic polyadenylation element (CPE), interacts with the human CPEB1 protein and directs maturation-dependent cytoplasmic polyadenylation of the endogenous Mos mRNA.

Abstract: Matrix metalloproteinases are major mediators of tissue destruction in various chronic inflammatory disorders. The present invention demonstrates that over-expression of intracellular isoform of IL-1 receptor antagonist confers to recipient cells resistance to signaling pathways of proinflammatory cytokines (such as tumor necrosis factor alpha and IL-1 beta) that induce matrix metalloproteinase and subsequent tissue degradation. Hence, over-expression of intracellular IL-1 receptor antagonist may inhibit tissue destruction in various inflammatory disorders such as rheumatoid arthritis, other arthritides, degenerative intervertebral disc disease and chronic skin ulcers that occurs in diabetes mellitus and bed-ridden patients.

Abstract: Provided herein is a device for altering a biological membrane in an individual comprising a means for delivering energy to the surface of said biological membrane; a means for monitoring a physiological state of said biological membrane during delivery of said energy; a means for modulating delivery of said energy to said biological membrane wherein said modulating is in response to a change in said monitored physiological state; and a housing means for said device. Also provided is a device to control the permeation of substance across a biological membrane and methods for use of these devices.

Abstract: The present invention provides a method of determining whether an individual is at risk for atherosclerosis, comprising the step of: measuring the level of carbamylated LDL in a sample obtained from said individual. Further provided is a method of reducing carbamylation in an individual in need of such reducing, comprising the step of: treating said individual with a monomeric amino acid or another enzymatic or non-enzymatic inhibitor of carbamylation. Also provided is a method of preventing carbamylation in an individual with normal renal function, comprising the step of: treating said individual with a monomeric amino acid. Further provided is a method of treating or preventing atherosclerosis in an individual in need of such reducing, comprising the step of: inhibiting aggregation and/or deposition of carbamylated LDL in said individual.

Abstract: To identify molecular determinants of lytic bone disease in multiple myeloma, the expression profiles of ˜12,000 genes in CD138-enriched plasma cells from newly diagnosed multiple myeloma patients exhibiting no radiological evidence of lytic lesions (n=28) were compared to those with ?3 lytic lesions (n=47). Two secreted WNT signaling antagonists, soluble frizzled related protein 3 (SFRP-3/FRZB) and the human homologue of Dickkopf-1 (DKK1), were expressed in 40 of 47 with lytic bone lesions, but only 16 of 28 lacking bone lesions (P<0.05). DKK1 and FRZB were not expressed in plasma cells from 45 normal bone marrow donors or 10 Waldenstrom's macroglobulinemia, a related plasma cells malignancy that lacks bone disease. These data indicate that these factors are important mediators of multiple myeloma bone disease, and inhibitors of these proteins may be used to block bone disease.

Abstract: The present invention provides uses of multi-nutrient supplements to rescue aberrant biochemical pathways and reduce birth defect caused by maternal diabetes. Choice of supplements is based on the ability of each supplement to correct the following hyperglycemia-associated abnormalities: increased reactive oxygen species generation, abnormal membrane phospholipid metabolism, and decreased glutathione synthesis.

Abstract: A system and method for adjusting the distribution of an asset over a multi-tiered network is provided. An asset may represent network and/or application components (e.g., data, objects, applications, program modules, etc.) that may be distributed among the various resources of the network. In an embodiment, a performance metric is received and input to a performance model. The model determines a network optimization and at least one change requirement based on the metric. A package specification is changed to reflect the requirement, which may specify that at least one asset should be packaged in at least one package. The change requirement is implemented and the package is distributed over the network.

Abstract: Pharmaceutical compositions of a benzimidazole or a benzimidazole derivative are disclosed. For example, in certain embodiments the pharmaceutical compositions include a benzimidazole, PEG 400, and a dipolar aprotic solvent. In other embodiments, pharmaceutical compositions include a benzimidazole, an oil, a dipolar aproptic solvent, and a surfactant. In certain embodiments, the benzimidazole is mebendezole. The pharmaceutical compositions are formulated for delivery to a subject by any means, and include formulations for oral and parenteral delivery.

Abstract: The present invention provides ratiometric fluorescent pH sensors for non-invasive, continuous monitoring of pH in such applications as fermentation processes. The ratiometric fluorescent pH sensors comprise a fluorescent dye that exhibits a shift in excitation wavelength with a corresponding shift in pH in the local environment of said fluorescent dye. Ratiometric measurements of the emission intensities at dual excitation maxima correlate to pH. Also provided is a fluorescent dye 6-methacryloyl-8-hydroxy-1,3-pyrene disulfonic acid (MA-HPDS). Further provided are systems and methods to non-invasively and continuously monitor pH.

Abstract: Provided herein are methods for measuring wave aberrations of the eye. Retinal scattered radiation from a probing laser beam is detected, the wave front tilt is measured as first partial derivatives along known coordinates in a discrete set of the pupil points, the wave front is approximated from this data as functions of the pupil coordinates and the wave aberrations of the eye are thereby calculated. Partial derivatives are determined at any pupil point by spline approximation using the values in a discrete number of points in which the wave front tilts are measured. This set of points may be located along concentric circles or along one of the orthogonal axes. The wave front is reconstructed using numerical integration along the radii with the initial integration point in the center of the pupil. Wave aberrations are calculated from wave front data reconstructed in the form of splines.